Page 157 - HIV/AIDS Guidelines

drug-drug interactions. Because ART may slow the progression of HCV-related liver disease, ART should be
considered for most HIV/HCV-coinfected patients, regardless of CD4 count. If treatment with PegIFN/RBV
alone or in combination with one of the HCV NS3/4A PIs (telaprevir or boceprevir) is initiated, the ART
regimen may need to be modified to reduce the potential for drug-drug interactions and/or drug toxicities that
may develop during the period of concurrent HIV and HCV treatment. The science of HCV drug
development is evolving rapidly. As new clinical trial data on the management of HIV/HCV-coinfected
patients with newer HCV drugs become available, the Panel will modify its recommendations accordingly.

References

1. Alter MJ, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties
Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992;327(27):1899-1905.

2. Thomas DL, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA.
2000;284(4):450-456.

3. Poynard T, Bedossa B, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The
OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825-832.

4. Wiley TE, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology.
1998;28(3):805-809.
5. Graham CS, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a
meta-analysis. Clin Infect Dis. 2001;33(4):562-569.
6. Thein HH, et al. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the
era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979-1991.
7. Weber R, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch
Intern Med. 2006;166(15):1632-1641.
8. Kitahata MM, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med.
2009;360(18):1815-1826.
9. Greub G, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1
and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356(9244):1800-1805.
10. Vlahov D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma
viral load and CD4+ cell count. JAMA. 1998; 279(1):35-40.
11. Celentano DD, et al. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280(6):544-546.
12. Sulkowski MS, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human
immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74-80.
13. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing
antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35(1):182-189.
14. Poordad F, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-1206.
15. Jacobson IM, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med.
2011;364(25):2405-2416.
16. Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic infections
in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV
Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1-207.
17. Ghany MG, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.
18. Ghany MG, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by
the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-1444.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents J-9

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.